ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.1_2632
Abstract: Roche, Janssen, Takeda, MSD, Gilead, Bristol Myers Squibb, AstraZenecca; Research Funding: Celgene, Roche, Abbvie; Other Remuneration: Roche, Amgen. Chu, M: Honoraria: AstraZeneca, Gilead, Celgene. Dreyling, M: Honoraria: Bayer, Celgene, Gilead, Janssen, Roche, Acerta, Bayer, Celgene,… read more here.
Keywords: janssen; roche; research funding; celgene ... See more keywords
EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.43_2630
Abstract: Pharma/Astra Zeneca, Celgene. Janssen; Honoraria: Abbvie, Acerta Pharma/Astra Zeneca, Celgene. Janssen, Gilead Sciences, Roche/Genentech, TG Therapeutics; Research Funding: Acerta Pharma/Astra Zeneca, Janssen, Celgene. Trneny, M: Consultant Advisory Role: Takeda, BMS, Incyte, Abbvie, Amgen, Roche, Gilead,… read more here.
Keywords: hematology; advisory role; celgene; consultant advisory ... See more keywords
MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR)
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.75_2631
Abstract: Research Funding: Acerta Pharma. Schuster, S: Consultant Advisory Role: Novartis, Nordic Nanovector, Celgene, Merck, Gilead, Pfizer; Honoraria: Genentech, Novartis, Nordic Nanovector, Celgene, Merck, OncLive, Dava Oncology, Physician's Education Source, LLC; Research Funding: Genentech, Novartis, Nordic… read more here.
Keywords: rituximab; oncology; celgene; research funding ... See more keywords
A cross‐sectional study of psoriasis triggers among different ethno‐racial groups
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2017.04.1109
Abstract: Dr Bissonnette has received grants and research support, served as a consultant or received honoria from AbbVie, Amgen, Apopharma, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK-Stiefel, Merck, Incyte, Janssen, Kineta, Leo Pharma, Merck, Novartis,… read more here.
Keywords: leo pharma; eli lilly; celgene; merck ... See more keywords
SAT0225 Cereblon modulator CC-220 decreases naÏve and memory B cells and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients: exposure-response results from a phase 2A proof of concept study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.3036
Abstract: Background CC-220 is a cereblon E3 ligase modulatory compound currently in development for the treatment of Systemic Lupus Erythematosus as well as other autoimmune conditions and multiple myeloma. As a high affinity ligand for cereblon,… read more here.
Keywords: sle; employee celgene; celgene employee; celgene ... See more keywords
AB0945 Secukinumab efficacy in patients with active psoriatic arthritis: pooled analysis of four phase 3 trials by prior anti-tnf therapy and concomitant methotrexate use
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2374
Abstract: Background Secukinumab has demonstrated rapid, significant and sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) in multiple Phase 3 studies.1–3 Objectives To report pooled efficacy results for secukinumab versus placebo at Week… read more here.
Keywords: celgene; anti tnf; janssen; novartis ... See more keywords
AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2983
Abstract: Background Tildrakizumab (TIL), a high affinity, humanised, IgG1/κ monoclonal antibody for IL-23p19, recently demonstrated efficacy in patients with chronic plaque psoriasis in two, phase 3 clinical trials. Objectives To examine efficacy from baseline to week… read more here.
Keywords: week; pfizer; celgene; pasi pasi ... See more keywords
AB0928 Ustekinumab and tnf inhibitors in psoriatic arthritis: first follow-up data from a routine care study in 8 european countries (PSABIO)
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.6939
Abstract: Background The purpose of PsABio (ClinicalTrials.gov Id: NCT02627768) is to evaluate the efficacy, tolerability and persistence of TNF inhibitors (TNFi) and ustekinumab (UST) for patients with psoriatic arthritis (PsA) starting 1st, 2nd or 3rd line… read more here.
Keywords: celgene; janssen; research support; pfizer ... See more keywords
FRI0429 NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAïVE, SYSTEMIC THERAPY-NäIVE) PSORIATIC DISEASE: A SYSTEMATIC REVIEW
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.1837
Abstract: Background Psoriatic disease (PsD) refers to a systemic condition, probably driven by chronic and complex inflammatory mechanisms. PsD patients experience a fickle mixture of cutaneous (nail dystrophy, psoriatic lesions spectrum) and musculoskeletal (MSK: arthritis, enthesitis,… read more here.
Keywords: lilly novartis; celgene; consultant; research ... See more keywords
FRI0437 PATIENT-DEFINED FLARES IN IN PSORIATIC ARTHRITIS: WHAT DO THEY MEAN? AN ANALYSIS OF CHANGE BETWEEN 2 VISITS IN 222 PATIENTS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.2161
Abstract: Background In psoriatic arthritis (PsA), disease fluctuations lead to periods of flares which impact patients’ lives and treatment retention, these flares have been little studied. Objectives To explore the frequency of flares in patients with… read more here.
Keywords: pfizer; novartis pfizer; disease; celgene ... See more keywords
THU0358 DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.4555
Abstract: Background: There is wide variation in the management of patients with axial spondyloarthritis (axSpA) worldwide with significant unmet needs such as delayed diagnosis. A major goal of the international organization Assessment of SpondyloArthritis international Society… read more here.
Keywords: none declared; pfizer; novartis pfizer; celgene ... See more keywords